Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting
NCT04694248Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2021
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of rivaroxaban and aspirin in deep vein thrombosis (DVT) and iliac vein stenosis (IVS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Primary Effectiveness Endpoint: Patency of iliac vein at 12 months and Primary Safety Endpoint at 12 months. Started Nov 2021; status: recruiting.
02
Drugs
rivaroxabanaspirin
03
Conditions
deep vein thrombosis (DVT)iliac vein stenosis (IVS)
Beyond the preview
Go deeper on NCT04694248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04694248.